Physician profile

Mark Jason

Laguna Hills, CA

NPI 1629179536

$4,793.59

in general payments reported to CMS, 2019-2025

16 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,441.85 2019-2022
Lilly USA, LLC $1,014.51 2019-2022
Abbvie INC. $673.99 2019-2021
Janssen Biotech, INC. $440.01 2019-2021
Celgene Corporation $273.16 2019
Pfizer INC. $256.73 2019-2021
E.R. Squibb & Sons, L.L.C. $146.73 2019-2021
Novartis Pharmaceuticals Corporation $105.69 2019-2021
Genzyme Corporation $94.44 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $74.98 2019-2020
Glaxosmithkline, LLC. $71.20 2019-2021
Mallinckrodt Enterprises LLC $66.85 2019
Horizon Therapeutics Plc $48.43 2019-2020
Genentech USA, INC. $40.27 2019
Astrazeneca Pharmaceuticals Lp $28.98 2021
Show all 16 companies
CompanyGeneral paymentsYearsTop products
Mallinckrodt Hospital Products INC. $15.77 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Jason

$4,793.59

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/28598/mark-jason

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.